Lifeloc Technologies Annual Shareholders Meeting May 17, 2023



Committed to safer roads and workplaces worldwide



Lifeloc Technologies

Safe Harbor Agreement

This presentation contains forward-looking statements which reflect management's expectations regarding Lifeloc's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Where possible words such as "plans," "expects" or "does not expect," "budget," "forecasts," "anticipates" or "does not anticipate," "believes," "intends" and similar expressions or statements that certain actions, events or results "may," "could," "would," "might" or "will" be taken, occur or be achieved, have been used to identify these forward-looking statements. Although the forward-looking statements contained in this presentation reflect management's current assumptions based upon information currently available to management and based upon that which management believes to be reasonable assumptions, Lifeloc cannot be certain that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Lifeloc's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: international and domestic operations, customer demand, regulatory matters credit and customer concentration; competition; rapid technological change; product liability claims; intellectual property; use of non-GAAP financial measures; significant kareholder; supply arrangements; and dependence upon key management personnel and executives. For more details, please see the "Risk Factors" section of our SEC filing.

Although Lifeloc has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Accordingly, as noted above, you should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this presentation and, except as required by law, Lifeloc assumes no obligation to update or revise them to reflect new events or circumstances.





Post Pandemic

The pandemic and supply chain have dominated company agenda

- Benefit from both rounds of PPP as well as ERTC
- Sales recovered
- Supply chain challenges constrained 2022 sales
- Broad price increases

5

2022 Income Statement			
2022 meome statement			
		1	
Income Statement	2022	2021	
Revenue	\$ 8,481,993	\$ 7,054.430	
Gross Profit	\$ 3,074,951	\$ 3,060,096	
Gross Margin	36.3%	43.4%	
R&D	\$ 1,385,927	\$ 1,213,482	
Sales	\$ 1,112,526	\$ 1,003,983	
General and Admin	\$ 1,216,843	\$ 1,111,544	
PPP, ERTC Benefit	\$ 107,575	\$ 936,444	
Pretax Income	\$ (572,737)	\$ 619,660	
Net Income	\$ (455,757)	\$ 675,967	

6

Immediate Contributors	Now exiting the constrained supply,
	ramp up sales and marketing
	New Platform LX9 and LT7
Ultimate Target	Lifeloc seeks to grow and exceed
	\$100 million
	With real time drug testing via SpinD>



New Platform LX9 and LT7



LT7 is the value model

Temperature range -10°C to 55°C

Ambidextrous

This line is now sold in more than 25 countries



Rapid Drug Testing


- The rapid drug testing market remains our best opportunity for major growth.
- The drug testing needs are enormous and growing.
- Growing marijuana legalization is normalizing abuse. Legalization only increases the need rapid drug detection.
- The recently issued U.S. DOT rule requiring the availability of oral fluids as a drug testing option have raised the value and urgency for the first SpinDx offering.




SpinDx Development Status

- Four Lifeloc designed prototypes have been built
- Hardware and assay being optimized
- R&D team expanding, with SpinDx commercialization as primary objective
- Patent application filed for enhancing Δ9-THC specificity beyond Sandia developments
- Graphical user interface in development






Test in Progress				
TEST	INPROGRES	SS 12:30P		
 O Cocaine O Methamphetamine O Amphetamine O THC O Opioids O Benzodiazepine O Ketamine 	SERIAL # 1 Date 0	BASIC PANEL 10-2023-0410037 04/10/2023 12:30 PM		
		PRINT RESULT		







Lifeloc Growth Summary

Nurture the core business with feature expansion and sales expansion to maximize cash flow.

Cash flow from the core is expected to continue to fund the ultimate growth target of real time drug testing to avoid or minimize shareholder dilution.

